Brief: Rhythm Pharmaceuticals Announces Clinical Development Plan Of Setmelanotide For Hypothalamic Obesity In Japan
22/02/2024 14:25
Feb 22 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O :
* RHYTHM PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT PLAN
OF
SETMELANOTIDE FOR HYPOTHALAMIC OBESITY IN JAPAN
* RHYTHM-SUPPLEMENTAL COHORT OF 12 JAPANESE PATIENTS TO BE
ADDED
TO GLOBAL PHASE 3 HYPOTHALAMIC OBESITY TRIAL, WITH DOSING
EXPECTED TO BEGIN IN Q3 2024
Source text for Eikon: ID:nGNX8PDXZ2
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand